Neuroinflammation in Parkinson's disease: A role for matrix metalloproteinases?

Neuroinflammation: Pathogenesis, Mechanisms and Management

Volumn , Issue , 2012, Pages 65-88

  De Stefano, Maria Egle ^a,b   Annese, Valentina ^a   Barcia, Carlos ^c   Ros Bernal, Francisco ^c   Fernández Villalba, Emiliano ^c   Herrero, Maria Trinidad ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF MURCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895242076     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (202)

1. Streit WJ, Conde JR, Fendrick SE, Flanary BE, Mariani CL. Role of microglia in the central nervous system's immune response. Neurol Res 2005, 27:685-91.
2. Popovich PG, Longbrake EE. Can the immune system be harnessed to repair the CNS? Nature Rev Neurosci 2008, 9:481-93.
3. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009,10:23-36.
4. McFarland HF, Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007,8:913-9.
5. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010,140:918-34.
6. Siffrin V, Vogt J, Radbruch H, Nitsch R, Zipp F. Multiple sclerosis -candidate mechanisms underlying CNS atrophy. Trends Neurosci 2010,33:202-10.
7. Yong VW. Inflammation in neurological disorders: a help or a hindrance? Neuroscientist 2010,16:408-20.
8. McGeer PL, Schwab C, Parent A, Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration Ann Neurol 2003,54:599-604.
9. Zipp F, Aktas O. The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2066,29:518-27.
10. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002,40:133-9.
11. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003,53:292-304.
12. Correale J, Villa A. ì The neuroprotective role of inflammation in nervous system injuries. J Neurol 2004,251:1304-16.
13. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009,32:638-47.
14. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet J 2011,10:253-63.
15. Verkhratsky A, Toescu EC. Neuronal-glial networks as substrate for CNS integration. J Mol Med 2006,10:826-36.
16. Kettenmann H, Verkhratsky A. Neuroglia: the 150 years after. Trends Neurosci 2008,31:653-9.
17. Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci 2009,32:421-31.
18. Verkhratsky A. Neuronismo y reticulismo: neuronal-glial circuits unify the reticular and neuronal theories of brain organization. Acta Physiol 2009,195:111-22.
19. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996,19:312-8.
20. Nishiyama A, Komitova M, Suzuki R, Zhu X. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat Rev Neurosci 2009,10:9-22.
21. Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F, Xu Q, Wyatt JD, Pilcher W, Ojemann JG, Ransom BR, Goldman SA, Nedergaard M. Uniquely hominid features of adult human astrocytes. J Neurosci 2009,29:3276-87.
22. Raivich G, Botatchek M, Kloss CU, Werner A, Jones LL, Kreutzberg GW. Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Rev 1999,30:77-105.
23. Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Progr Neurobiol 1999,57:563-81.
24. Hanish U-K, Kettenman H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nature Neurosci 2007,10.1387-94.
25. Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010,119:7-35.
26. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988,38:1285-91.
27. Aloisi F, Ria F, Adorini L Regulation of T cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000,21:141-7.
28. Narassimahan K. Brain's guard cells show their agility. Nature Neurosci 2005, 8:752-8.
29. Kettenmann H. Triggering the brain's pathology sensor. Nat Neurosci 2006,9:1463-4.
30. Kettenmann H. Neuroscience: the brain's garbage men. Nature 2007,446:987-9.
31. Napoli I, Neumann H. Microglial clearance function in health and disease. Neuroscience 2009,158:1030-8.
32. Voskuhl RR, Peterson RS, Song B, Ao Y, Morale LBJ, Tiwari-Woodruff S, Sofroniew MV. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 2009,29:11511-22.
33. McGeer PL, McGeer EG. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2001,26:459-70.
34. Rossi D, Brambilla L, Valori CF, Roncoroni C, Crugnola A. Yokota T, Bredesen DE, Volterra A. Focal de generation of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ 2008,15:1691-1700.
35. Rossi D, Volterra A. Astrocytic dysfunction: insights on the role in neurodegeneration. Brain Res Bull 2009,80:224-32.
36. Badie B, Scharter J, Vorpahl J, Preston K. Interferon-gamma induces apoptosis and augments the expression of Fas and Fas ligand by microglia in vitro. Exp Neurol 2000,162:290-6.
37. Lee YB. Nagai A, Kim SU. Cytokines, chemokines, and cytokine receptors in human microglia. J Neurosci Res 2002,69:94-103.
38. Taylor DL. Jones F, Kubota ES, Pocock JM. Stimulation of microglia metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor a-induced neurotoxicity in concert with microglial-derived fas ligand. J Neurosci 2005,25:2945-64.
39. Miller G. The dark side of glia. Science 2005,308:778-81.
40. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci 2007,8: 221-32.
41. Lofrumento DD, Saponaro C, Cianciulli A, De Nuccio F, Mitolo V, Nicolardi G, Panaro MA. MPTP-induced neuroinflammation increases the expression of pro-inflammatory cytokines and their receptors in mouse brain. Neuroimmunomodulation 2011,18:79-88.
42. Neumann H, Wekele H. Neuronal control of the immune response in the central nervous: linking brain immunity to neurodegeneration. Neurophathol Exp Neurol 1998,57:1-9.
43. Appel SH. CD4+ T cells mediate cytotoxicity in neurodegenerative diseases. J Clin Invest 2009,119:13-15.
44. Matute C. P2X7 receptors in oligodendrocytes: a novel target for neuroprotection. Mol Neurobiol 2008,38:23-8.
45. van der Valk P, Amor S. Preactive lesions in multiple sclerosis. Curr Opin Neurol 2009,22:207-13.
46. van Swieten JC, Caplan LR. Binswanger's disease. Adv Neurol 1993,62:193-211.
47. Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord Suppl 2009,3:S200-4.
48. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009,8:382-97.
49. Mizuno Y, Hattori N, Kitada T, Matsumine H, Mori H, Shimura H, Kubo S, Kobayashi H, Asakawa S, Minoshima S, Shimizu N. Familial Parkinson's disease. Alpha-synuclein and parkin. Adv Neurol. 2001,86:13-21.
50. Gwinn-Hardy K. Genetics of Parkinsonism. Mov Disord 2002,17:645-56.
51. Hirsh EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998,44:S115-20.
52. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The role of glial reaction and inflammation in Parkinson's disease. Ann NY Acad Sci 2003,991:214-28.
53. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur N, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2006,24:197-211.
54. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998,339:1130-43.
55. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 2002,175:303-17.
56. Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003,110:517-36.
57. Halliday G, Herrero MT, Murphy K, McCann H, Ros-Bernal F, Barcia C, Mori H, Blesa FJ, Obeso JA. No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov Disord 2009,24:1519-23.
58. Gandhi S, Wood NW. Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 2005,14: 2749-55.
59. Vila M, Jackson-Lewis V, Guégan C, Chu Wu D, Teismann P, Choi D-G, Tieu K. Przedborski S. The role of glial cells in Parkinson's disease. Current Opinion in Neurology 2001,14:483-9.
60. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005,11:999-1016.
61. Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 2007,35:1127-32.
62. McGeer PL, McGeer EG. Glial reaction in Parkinson's disease. Mov Disord 2008,23:474-83.
63. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinspn's disease. J Brit Pharmacol 2007,150:936-76.
64. Heneka MT, Rodriguez JJ. Verkhratsky A. Neuroglia in neurodegeneration. Brain Res Rev 2010,63.189-211.
65. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implication for therapeutic intervention. Neurobiol Dis 2010,37:510-8.
66. McGeer PL. Rate of cell death in Parkinsonism indicates active neuropathological process. Ann Neurol 1998,24:574-6.
67. Forno LS. Neuropathologic features of Parkinson's, Huntington's, and Alzheimer's diseases. Ann N Y Acad Sci 1992,648:6-16.
68. Gerhard A, Pavese N, Hotton G, Turkheimer FEM, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006,21:404-12.
69. Braak H, Sastre M, Del Tredici K. Development of a-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol 2007,114: 231-41.
70. Rowe DB, Le W, Smith RG, Appel SH. Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res 1998,53:551-8.
71. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995,202:17-20.
72. Muller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998,98:142-4.
73. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005,57:168-75.
74. Rodriguez M, Barroso-Chinea P, Abdala P, Obeso J, Gonzalez-Hernandez T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson's disease. Exp Neurol 2001,169:163-81.
75. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003,23:10756-64.
76. Barcia C, Sánchez-Bahillo A, Fernández-Villalba E, Bautista V, Poza Y, Poza M, Fernández-Barreiro A, Hirsch EC, Herrero MT. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004,46:402-9.
77. Barcia C, de Pablos V, Bautista-Hernández V, Sánchez-Bahillo A, Bernal I, Fernández-Villalba E, Martín J, Bañón R, Fernández-Barreiro A, Herrero MT. Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism Relat Disord 2005,11:435-9.
78. Barcia C, Ros CM, Annese V, Gómez A, Ros-Bernal F, Aguado-Yera D, Martínez-Pagán ME, de Pablos V. Fernandez-Villalba E, Herrero MT. IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death & Disease 2011:2,e142.
79. Mena MA, Garcia de Yebenes J. Glial cells as players in Parkinsonism: the "good," the "bad," and the "mysterious" glia. Neuroscientist 2008,14: 544-60.
80. Bamum CJ, Tansey MG. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res 2010,184:113-32.
81. Walsh S, Finn DP, Dowd E. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat. Neuroscience 2011,175:251-61.
82. Breidert T, Callebert J, Heneka MT, Landreth NG, Launay JM. Hirsch EC. Protective action of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002,82:615-24.
83. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999,46:598-605.
84. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996,72:355-63.
85. Nagatsu T, Mogi M, Ichinose H, Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. Neural Transm Suppl 2000,60:277-90.
86. Nagatsu T. Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy. J Neural Transm 2002,109:731-45.
87. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ. Central and systemic IL-I exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 2008,131:1880-94.
88. Ré DB, Przedborski S. Fractalkine: moving from chemotaxis to neuroprotection. Nature Neurosci 2006,9:859-61.
89. Bacon KB, Harrison JK. Chemokines and their receptors in neurobiology: perspectives in physiology and homeostasis. J Neuroimmunol 2000,104: 92-7.
90. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang DR, Kidd G, Dombrowsk S, Dutta R, Lee J-C, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. Control of microglial neurotoxicity by the fractalkine receptor. Nature Neurosci 2006,9:917-24.
91. Mizuno T, Kawanokuchi J, Numata K, Suzumura A. Production and neuroprotective functions of fractalkine in the central nervous system. Brain Research 2003,979:65-70.
92. Pabon MM, Bachstetter AD, Hudson CE, Gemma C, Bickford PC. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. J Neuroinfl 2011,8:9.
93. Shan S, Hong-Min T, Yi F, Jung-Peng G, Yue F, Yan-Hong T, Yun-Ke Y, Wen-Wei L, Xiang-Yu W, Jun M, Guo-Hua W, Ya-Ling H, Hua-Wei L, Ding-Fang C. New evidence for fractalkine/CX3CL1 involved in substantia nigra microglial activation and behavioral changes in a rat model of Parkinson's disease. Neurobiol Aging 2009,32:443-58.
94. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi D-K, Ischiropoulos H, Predborsi S. Blockade of microglial activation is neuroprotective in the 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci 2002,22:1763-71.
95. Kim YS, Choi DH, Block ML, Lorenzl S, Yang L, Kim YJ, Sugama S, Cho BP, Hwang O, Browne SE, Kim SY, Hong J-S, Beal MF, Joh TH. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J 2007,21:179-80.
96. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, Anisman H, Hayley S, Park DS. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci 2007,27:3328-237.
97. Mena MA, Casarejos MJ, Garcia de Yebenes J. The effect of glia-conditioned medium on dopamine neurons in culture. Modulation of apoptosis, tyrosine hydroxylase expression and 1-methyl-4-phenylpyridinium toxicity. J Neural Transm 1999,106:1105-23.
98. Mena MA. de Bernardo S, Casarejos MJ, Canals S, Rodriguez-Martin E. The role of astroglia on the survival of dopamine neurons. Mol Neurobiol 2002,25:245-63.
99. Annese V, Barcia C, Gomez A, Ros-Bernal F, Fernandez-Villalba E, Paggi P, De Stefano ME, Herrero MT. Striatal oligodendrocytosis and increased oligodendrocyte/neuron expression of metalloproteinase-9 by acute and chronic MPTP treatment (both in mice and monkeys). Presented at the 7th Forum of European Neuroscience, July 2010, Abstract 197.2.
100. Franklin RJM, ffrench-Constant C. Remyelination in the CNS: from biology to therapy Nature Rev Neurosci 2008,9:839-55.
101. Gao HM, Liu B, Zhang W, Hong JS. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 2003,24:395-401.
102. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011,76:863-9.
103. Bosman FT, Stamenkovic I. Functional structure and composition of the extracellular matrix. J Pathol 2003,200:423-8.
104. Dityatev A, Bukalo O, Schachner M. Modulation of synaptic transmission and plasticity by cell adhesion and repulsion molecules. Neuron Glia Biol 2008,4:197-209.
105. Wright JW, Harding JW. Contributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction. Neural Plast 2009, doi:10.1155/2009/579382.
106. Faissner A, Pika M, Geissler M, Sobik T, Frischknecht R, Gundelfinger ED, Seidenbecher C. Contributions of astrocytes to synapse formation and maturation -Potential functions of the perisynaptic extracellular matrix. Brain Res Rev 2010,63:26-38.
107. Fields RD, Itoh K. Neural cell adhesion molecules in activity-dependent development and synaptic plasticity. Trends Neurosci 1996,19:473-80.
108. Dityatev A, Fellin T. Extracellular matrix in plasticity and epileptogenesis. Neuron Glia Biol 2009,4:235-47.
109. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behaviour. Annu Rev Cell Dev Biol 2001,17:463-516.
110. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nature Rev Neurosci 2005,6:931-44.
111. Bonneh-Barkay D, Wiley CA. Brain extracellular matrix in neurodegeneration. Brain Pathol 2009,19:573-85.
112. Candelario-Jalil E, Yang Y, Rosenberg GA. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009,158:983-94.
113. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodeling. Nature Rev Mol Cell Biol 2007,8:221-33.
114. Michaluk P, Kaczmarek L. Matrix metalloproteinase-9 in glutamate-dependent adult brain function and dysfunction. Cell Death Diff 2007,14:1255-8.
115. Adibhatla RM, Hatcher JF. Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 2008,7:243-53.
116. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004,16:558-64.
117. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001,13:534-40.
118. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nature Rev Immunol 2004,4:617-29.
119. Dzwonek J, Rylski M, Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 2004,567:129-35.
120. Bridges LC, Bowditch RD. ADAM-integrin interactions: potential integrin regulated ectodomain shedding activity. Curr Pharm Des 2005,11:837-47.
121. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003,102:1186-95.
122. Rosemberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998,29:2189-95.
123. Heo JH, Lucero J, Abumiya T, Koziol JA, Copeland BR, del Zoppo GJ. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999,19:624-33.
124. Yang Y, Estrada EY, Thompson JF, Liu W, Rosenberg GA. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007,27:697-709.
125. Wang L, Zhang ZG, Zhang RL, Gregg SR, Hozeska-Solgot A, LeTourneau Y, Wang Y, Chopp M. Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration. J Neurosci 2006,26:5996-6003.
126. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, Wang X, Lo EH. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med 2006,12:441-5.
127. Kim KS, Kim HY, Joe EH, Jou I. Matrix metalloproteinase-3 induction in rat brain astrocytes: focus on the role of two AP-1 elements. Biochem J 2008,410:605-11.
128. Gottschall PE, Yu X. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J Neurochem 1995,64:1513-20.
129. Rosemberg GA, Cunningaìham LA, Wallace J, Alexander S, Estrada EY, Grossetete M, Razhagi J, Miller K. Gearing A. Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain Res 2001,893.104-12.
130. Lee WJ, Shin CY, Yoo BK, Ryu JR, Choi EY, Cheong JH, Ryu JH, Ko KH. Induction of MMP-9 in lipopolysaccharide-stimulated primary astrocytes is mediated by extracellular signal-regulated protein kinase1/2. Glia 2003,41:15-24.
131. Kauppinen TM, Swanson RA. Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J Immunol 2005,174:2288-96.
132. Crocker SJ, Milner R, Pham-Mitchell N, Campbell IL. Cell and agonist-specific regulation of genes for matrix metalloproteinases and their tissue inhibitors by primary glial cells. J Neurochem 2006,98:812-23.
133. Mun-Bryce S, Rosenberg GA. Gelatinase B modulates selective opening of the blood-brain barrier during inflammation. Am J Physiol 1998,274:R1203-11.
134. Gurney KJ, Estrada EY, Rosenberg GA. Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiol Dis 2006,23:87-96.
135. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 1995,703:151-5.
136. Candelario-Jalil E, Taheri S, Yang Y, Sood R, Grossetete M, Estrada MY, Fiebich BL, Rosenberg GA. Cyclooxygenase inhibition limits blood-brain barrier disruption following injection of tumor necrosis factor-a in the rat. J Pharmacol Exp Ther 2007,323:488-98.
137. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993,192:1175-81.
138. Ito A, Mukaiyama A, Itoh Y, Nagase H, Thøgerseni IB, Enghildi JJ, Sasaguri Y, Mori Y. Degradation of interleukin 1β by matrix metalloproteinases. J Biol Chem 1996,271:14657-60.
139. McQuibban G, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000,289:1202-6.
140. Van Den Steen PE, Wuyts A, Husson SJ, Proost P, Van Damme J, Opdenakker G. Gelatinase B/MMP-9 and neutrophil collagenase/MMP-8 process the chemokines human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-2/LIX and modulate their physiological activities. Eur J Biochem 2003,270:3739-49.
141. Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007,82:1375-81.
142. Vos CM, Gartner S, Ransohoff RM, McArthur JC, Wahl L, Sjulson L, Hunter E, Conant K. Metalloprotease-9 release from monocytes increases as a function of differentiation: implications for neuroinflammation and neurodegeneration. J Neuroimmunol 2000,109:221-7.
143. Matias-Roman S, Gálvez BG, Genís L, Yáñez-Mó M, de la Rosa G, Sánchez-Mateos P, Sánchez-Madrid F. Arroyo AG. Membrane type 1-matrix metalloproteinase is involved in migration of human monocytes and is regulated through their interaction with fibronectin or endothelium. Blood 2005,105:3956-64.
144. Ogier C, Bernard A, Chollet AM, Le Diguardher T, Hanessian S, Charton G, Khrestchatisky M, Rivera S. Matrix metalloproteinase-2 (MMP-2) regulates astrocyte motility in connection with the actin cytoskeleton and integrins. Glia 2006,54:272-84.
145. Sithu SD, English WR, Olson P, Krubasik D, Baker AH, Murphy G, D'Souza SE. Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem 2007,282:25010-9.
146. Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, Holden J, Clark-Lewis I, Overall CM, Power C. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci 2003,6:1064-71.
147. Xue M, Hollenberg MD, Yong VW. Combination of thrombin and matrix metalloproteinase-9 exacerbates neurotoxicity in cell culture and intracerebral hemorrhage in mice. J Neurosci 2006,26:10281-91.
148. Jorquin J. Tremblay E, Decanis N, Charton G, Hanessian S, Chollet AM, Le Diguardher T, Khrestchatisky M, Rivera S. Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainite. Eur J Neurosci 2003,18:1507-17.
149. Cardone M, Salvesen GS, Widman C, Johnson G, Frisch SM. The regulation of anoikis: MEKK-1 activation requires caspase activation. Cell 1997,90:315-23.
150. Zalewska T, Ziemka-Nalecz M, Sarnowska A, Domanska-Janik K. Involvement of MMPs in delayed neuronal death after global ischemia. Acta Neurobiol Exp (Wars) 2002,62:53-61.
151. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Liton SA. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005,25:6401-8.
152. Guo ZD, Zhang XD, Wu HT, Lin B, Sun XC, Zhang JH. Matrix metalloproteinase 9 inhibition reduces early brain injury in cortex after subarachnoid hemorrhage. Acta Neurochir Suppl 2011,110:81-4.
153. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, Smith JW, Liddington RC, Lipton SA. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002,297:1186-90.
154. Agrawal SM, Lau L, Yong VW. MMPs in the central nervous system: where the good guys go bad. Semin Cell Dev Biol 2008,19:42-51.
155. Larsen PH, Wells JE, Stallcup WB, Opdenakker G, Yong VW. Matrix metalloproteinase-9 facilitates remyelination in part by processing the inhibitory NG2 proteoglycan. J Neurosci 2003,23:11127-35.
156. Reeves TM, Prins ML, Zhu JP, Povlishock JT, Phillips LL. Matrix metalloproteinase inhibition alters functional and structural correlates of deafferentation-induced sprouting in the dentate gyrus. J Neurosci 2003,23:10182-9.
157. Shubayev VI, Myers RR Matrix metalloproteinase-9 promotes nerve growth factor-induced neurite elongation but not new sprout formation in vitro. J Neurosci Res 2004,77:229-39.
158. Demestre M, Wells GM, Miller KM, Smith KJ, Hughes RA, Gearing AJ, Gregson NA. Characterisation of matrix metalloproteinases and the effects of a broad-spectrum inhibitor (BB-1101) in peripheral nerve regeneration. Neuroscience 2004,124:767-79.
159. Ahmed Z, Dent RG, Leadbeater WE, Smith C, Berry M, Logan A. Matrix metalloproteases: degradation of the inhibitory environment of the transected optic nerve and the scar by regenerating axons. Mol Cell Neurosci 2005,28:64-78.
160. Charalambous P, Hurst LA, Thanos S. Engrafted chicken neural tube-derived stem cells support the innate propensity for axonal regeneration within the rat optic nerve. Inv Ophthalmol Vis Sci 2008,49:3513-24.
161. Liu R, Chen XP, Tao LY Regulation of axonal regeneration following the central nervous system injury in adult mammalian. Neurosci Bull 2008,24:395-400.
162. Filous AR, Miller JH, Coulson-Thomas YM, Horn KP, Alilain WJ, Silver J. Immature astrocytes promote CNS axonal regeneration when combined with chondroitinase ABC. Dev Neurobiol 2010,70:826-41.
163. Kobayashi H, Chattopadhyay S, Kato K, Dolkas J, Kikuchi S, Myers RR, Shubayev VI. MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage. Mol Cell Neurosci 2008,39:619-27.
164. Chattopadhyay S, Shubayev VI. MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway Glia 2009,57:1316-25.
165. Larsen PH, DaSilva AG, Conant K, Yong VW. Myelin formation during development of the CNS is delayed in matrix metalloproteinase-9 and -12 null mice. J Neurosci 2006,26:2207-14.
166. Uhm JH, Dooley NP, Oh LY, Yong VW. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 1998,22:53-63.
167. Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z, Yong VW. Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 1999,19:8464-75.
168. Larsen PH, Yong VW. The expression of matrix metalloproteinase-12 by oligodendrocytes regulates their maturation and morphological differentiation. J Neurosci 2004,24.7597-603.
169. Meighan SE, Meighan PC, Choudhury P, Davis CJ, Olson ML, Zornes PA, Wright JW, Haring JW. Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J Neurochem 2006,96:1227-41.
170. Nagy V, Bozdagi O, Matynia A, Balcerzyk M, Okulski P, Dzwonek J, Costa RM, Silva AJ, Kaczmarek L, Huntley G. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 2006,26:1923-34.
171. Bodzagi O, Nagy V, Kwel KT, Huntley W. In vivo roles for matrix metalloproteinase-9 in mature hippocampal synaptic physiology and plasticity. J Neurophysiol 2007,98:334-44.
172. Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek J, Jaworski J, Gorecki DC, Ottersen OP, Kaczmarek L. β-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J Biol Chem 2007,282:16036-41.
173. Michaluk P, Mikasova L, Groc L, Frischknecht R, Choquet D, Kaczmarek L. Matrix metalloproteinase-9 controls NMDA receptor surface diffusion through integrin beta1 signaling. J Neurosci 2009,29:6007-12.
174. Rosemberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009,8:205-16.
175. Antony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997,23:406-15.
176. Cunningam LA, Wetzei M, Rosenberg GA. Multiple roles for MMPs and TIPs in cerebral ischemia. Glia 2005,50:329-39.
177. Guo M, Cox B, Mahale S, Davis W, Carranza A, Hayes K, Sprague S, Jimeneza D, Dinga Y. Pre-ischemic exercise reduces matrix metalloproteinase-9 expression and ameliorates blood-brain barrier dysfunction in stroke. Neuroscience 2008,151:340-51.
178. Wilczynski GM, Konopacki FA, Wilczek E, Lasiecka Z, Gorlewicz A, Michaluk P. Wawrzyniak M, Malinowska M, Okulski P, Kolodziej LR, Konopka W, Duniec K, Mioduszewska B, Nikolaev E, Walczak A, Owczarek D, Gorecki DC, Zuschratter W, Ottersen OP, Kaczmarek L. Important role of matrix metalloproteinase 9 in epileptogenesis. J Cell Biol 2008,180:1021-35.
179. Miller JP, Holcomb J, Al-Ramahi I, de Haro M, Gafni J, Zhang N, Kim E, Sanhueza M, Torcassi C, Kwak S, Botas J, Hughes RE, Ellerby LM. Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in Huntington's disease Neuron 2010,67.199-212.
180. Lorenzl S, Albers DS, LeWitt PA, Chirichigno JW, Hilgenberg SL, Cudkowicz ME, Beal MF. Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases. J Neurol Sci 2003,207:71-6.
181. Adair JC, Charlie J, Dencoff JE, Kaye JA, Quinn JF, Camicioli RM, Stetler-Stevenson WG, Rosenberg GA. MMP-9 in the cerebrospinal fluid of patients with vascular dementia and Alzheimer disease. Stroke 2004,35:e159-e162.
182. Lorenzl S, Albers DS, Narr S, Chirichigno J, Beal MF. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. Exp Neurol 2002,178:13-20.
183. Lorenzl S, Calingasan N, Yang L, Albers DS, Shugama S, Gregorio J, Krell HW, Chirichigno J, Joh T, Beal MF. Matrix metalloproteinase-9 is elevated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice. Neuromolecular Med 2004,5:119-32.
184. Hébert G, Arsaut J, Dantzer R, Demotes-Mainard J. Time-course of the expression of inflammatory cytokines and matrix metalloproteinases in the striatum and mesencephalon of mice injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, a dopaminergic neurotoxin. Neurosci Lett 2003,349:191-5.
185. Kim YS, Kim SS, Choi DH, Hwand O, Shin DH, Chun HS, Beal MF, Joh TH. Matrix metalloproinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J Neurosci 2005,25:3701-11.
186. Woo MS, Park JS, Choi IY, Kim WK, Kim HS. Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J Neurochem 2008,106:770-80.
187. Choi DH, Kim EM, Son HJ, Joh TH, Kim D, Beal MF, Hwang O. A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. J Neurochem 2008,106:405-15.
188. Choi DH, Hwang O, Lee KE, Lee J, Beal MF, Kim YS. DJ-1 cleavage by matrix metalloproteinase 3 mediates oxidative stress-induced dopaminergic cell death. Antioxid Redox Signal 2011, 14 (Epub ahead of print).
189. So HJ, Kwon KJ, Kim JW, Kim JW, Hasan MR, Lee HJ, Han SH, Shin CY. Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells. Neurosci Letters 2010,469:352-6.
190. Lee EJ, Woo MS, Moon PG, Baek MC, Choi IY, Kim WK, Junn E, Kim HS. Alpha-synuclein activates microglia by inducing the expression of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J Immunol 2010,185:615-23.
191. Hamil CE, Caudle WM, Richardson JR, Yuan H, Pennel KD, Greene JG, Miller GW, Traynelis SF. Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1. Mol Pharmacol 2011,72:653-64.
192. Levin J, Giese A, Boetzel K, Israel L, Högen T, Nübling G, Kretzschmar H, Lorenzl S. Increased a-synuclein aggregation following limited cleavage by certain matrix metalloproteinases. Exp Neurol 2009,215:201-8.
193. Gao H-M, Zhang F, Zhou H, Kam W, Wilson B, Hong J-S. Neuroinflammation and a-synuclein dysfunction potentiate each other driving chronic progression of neurodegeneration in a mouse model of parkinson's disease. 2001, doi: 10.1289/ehp.1003013 (available at http://dx.doi.org/).
194. Annese V, Barcia C, Ros Bernal F, Di Pentima M, Gomez A, Paggi P, Herrero MT, De Stefano ME. Extracellular proteases in experimental Parkinsonism: mRNA expression and protein synthesis of MMP-9, plasminogen and tissue-type plasminogen activator. Mov Dis 2009,24:S25 Suppl. 1.
195. De Stefano ME, Annese V, Barcia C, Di Pentima M, Gomez A, Paggi P, Herrero MT. Increase in matrix metalloproteinase-9 expression and activity in the striatum and substantia nigra of a mouse model of Parkinsonism. Oresented at the 40th Annual Meeting of the Society for Neuroscience, October 2009. Abstract 827.15.
196. Lorenzl S, Narr S, Angele B, Krell HW, Gregorio J, Kiaei M, Pfister HW, Beal MF. The matrix metalloproteinases inhibitor Ro 28-2653 [correction of Ro 26-2853] extends survival in transgenic ALS mice. Exp Neurol 2006,200:166-71.
197. Buss A, Pech K, Kakuas BA, Martin D, Schoenen, J, Noth J, Brook GA. Matrix metalloproteinases and their inhibitors in human traumatic spinal cord injury. BMC Neurol 2006, 26:7-17.
198. Leonardo CC, Hall AA, Collier LA, Gottschall PE, Pennypacker KR. Inhibition of gelatinase activity reduces neural injury in an ex vivo model of hypoxia-ischemia. Neuroscience 2009,160:755-66.
199. Chen W, Hartman R, Ayer R, Marcantonio S, Kamper J, Tang J, Zhang JH. Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. J Neurochem 2009,111:726-36.
200. Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000,31:3034-40.
201. Pfefferkorn T, Rosenberg GA. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 2003,34.2025-30.
202. Noble LJ. Donovan F, Igarashi T, Goussev S, Werb Z. Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events. J Neurosci 2002,22:7526-35.